Journal
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
Volume 102, Issue 2, Pages 128-131Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.ijgo.2008.04.008
Keywords
fluorescence in situ hybridization; HER2/neu; immunohistochemistry; serous papillary uterine cancer; trastuzumab; type 2 endometrial cancer
Categories
Ask authors/readers for more resources
Objective: To study the effect of trastuzumab in patients with progressive or recurrent metastatic endometrial carcinoma shown by immunohistochemistry to overexpress the HER2/neu receptor. Methods: Disease progression was examined in 2 patients who met the study criteria, had c-erbB2 gene amplification by fluorescence in situ hybridization, and were treated with trastuzumab following radiation treatment and/or salvage chemotherapy. Results: The clinical responses to trastuzumab as a single agent or in combination with chemotherapy were confirmed in both patients by serial CT scans and serum CA-125 evaluations. These patients with progressive or recurrent metastatic disease experienced relief from their symptoms and prolonged survival with no significant toxicity observed. Conclusion: Trastuzumab may be a viable therapeutic option as single agent or in combination with chemotherapy in patients with advanced, recurrent, and/or metastatic endometrial carcinomas overexpressing HER2/neu. (C) 2008 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available